The EPS projection of Medtronic, Inc. (NYSE:MDT) for period quarter completed 2017-01-31 is $1.15.
The EPS estimates given a week and 30-days ago were $1.15 and $1.15 correspondingly. This number 60 and 90 days before was $1.15 and $1.15 respectively. However, over last week ago, the change in EPS estimate is 0%.
For the quarter completed 1 mean estimate is $1.15 based on 19 EPS estimations. As on 2016-08-25 estimated EPS stood at $1.03 showing surprise of $0.02, or 1.98%. Following the disclosed forecasts, the standard deviation is $0.01.
The upgrade in EPS revisions were 0 a week earlier against negative revisions of 0. In last 1- month and 60-days, the upgrade in EPS revisions were 0 and 6 correspondingly, whereas for a quarter and 120-days earlier, it was 6 and 6 in that sequence.
The negative revisions of earnings per-share in the last 1-month and 60-days were 0 and 6 in that order. However, a quarter and 120-days earlier, this count was 6 and 5 correspondingly.
EPS revisions downgrade and upgrade in the last 18 days were 2 and 7, correspondingly.
Quarterly Sales Estimates
The arithmetic mean of apparent annual sales of Medtronic, Inc. (NYSE:MDT) is $9830.372 and the median is $9864.86. The estimate is stated by 5 analysts for the fiscal 2021.
The highest yearly projection is $10300.56 and lowest sales mark is $9311.39. This results a standard deviation of $357.017.
Almost 5 have revised sales target positively in the past week and 5 have downgraded forecasts. Depending on the stated estimates, the calculated change in target against the past week is 0%.
Nearly 5 revised sales projections positively over the past month and 5 have downgraded forecasts. It leads to a mean estimate deviation of -1.302%.
Just about 5 have revised sales forecast positively over the quarter and 5 have downgraded forecasts, giving a deviation of 0.115%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...